First Tracks Biotherapeutics

Forecast & Rating12 analysts currently cover First Tracks Biotherapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $70.00, about 118.7% upside from the current price of $32.01. Price targets range from $50.00 to $100.00 — a wide spread, showing clear disagreement over just how much First Tracks Biotherapeutics can rise. For you, this means most professionals who study First Tracks Biotherapeutics closely still see room for the stock to rise. Data as of Oct 2, 2026; for reference only and not investment advice.